PCM
ASMB icon

Prelude Capital Management’s Assembly Biosciences ASMB Stock Holding History

Prelude Capital Management’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-125
Closed -$18K – 1493
2016
Q4 		$18K Buy
+125
New +$18.6K ﹤0.01% 1321

Other funds holding ASMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Prelude Capital Management's ASMB Position: Q4 2020 in Review

Prelude Capital Management sold out of Assembly Biosciences (ASMB) in Q4 2020, closing a stake of 33 shares — an estimated $7K sold.

Prelude Capital Management first reported a position in ASMB in Q1 2015 and held it in 9 quarters. The position peaked at $118K in Q1 2018. 109 funds tracked by Wall St. Rank hold ASMB as of Q4 2020.

  • Prelude Capital Management reported no remaining Assembly Biosciences position as of Q4 2020 after selling out during the quarter.
  • Prelude Capital Management sold 33 Assembly Biosciences shares in Q4 2020, an estimated $7K.
  • Prelude Capital Management first reported a position in Assembly Biosciences in Q1 2015 and held it in 9 quarters.
  • Prelude Capital Management's Assembly Biosciences position peaked at $118K in Q1 2018.
  • 109 funds tracked by Wall St. Rank held Assembly Biosciences as of Q4 2020.

Based on Prelude Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.